Loading
A phase 2 trial of Tarlatamab in small-cell lung cancer, run by Amgen, active and no longer recruiting.
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment is a phase 2 interventional study registered as NCT06502977 by Amgen, with 32 participants enrolled, started 2024-08-27 and due to reach its primary completion in 2025-03-28. Interventions recorded: Tarlatamab. Conditions listed: Extensive Stage Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
32 enrolled.
95% CI 21.8 to 57.8; Figures from the ClinicalTrials.gov results section (first posted 2026-04-15), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)primary | Tarlatamab | 31 | 38.7% | - | - | link |
Shares Tarlatamab, Amgen, T-cell engagers (bispecific), Small-cell lung cancer.
Shares Tarlatamab, Amgen, T-cell engagers (bispecific), Small-cell lung cancer.
Shares Tarlatamab, Amgen, T-cell engagers (bispecific), Small-cell lung cancer.
Shares Tarlatamab, Amgen, T-cell engagers (bispecific), Small-cell lung cancer.
Shares Tarlatamab, Amgen, T-cell engagers (bispecific).
Shares Tarlatamab, Amgen, T-cell engagers (bispecific).
Shares Tarlatamab, Amgen, T-cell engagers (bispecific).
Shares Tarlatamab, Amgen, T-cell engagers (bispecific).